enhanced immune responses against hiv-1 with adenovector (gag and tat) prime/protein boost regimen and gm-csf injection

vaccines against the hiv-1 virus offers the best hope for eliminating hiv-associated mortality. recombinant adenovector type 5 (rad5) vaccine is a potential candidate for preventive vaccine strategies. in this study, we evaluated the rad5 prime/protein boost strategy in a murine model. we used rad5 harboring single hiv-1 genes. these genes, including gag (p24) and exon1 of tat, were amplified from hiv-1 (clade a) rna using nested pcr. recombinant vectors were constructed, purified and then injected at 10 12 viral particles into four groups, each comprising five mice. the groups were each assigned to receive one of rad5 prime/protein boost gag, tat with and without recombinant granulocyte-macrophage colony-stimulating factor (rgm-csf), and rad5 with and without genes. the humoral responses were evaluated using elisa and cellular immune responses checked by cell proliferation and elispot assays (il-2, il-4 and ifn-γ). it was shown that compared with the rad5 injection alone, the rad5 prime/protein boost plan increased cellular immunity ( p = 0.009) as well as humoral immunity ( p = 0.009). moreover, rgm-csf as an adjuvant enhanced cell-mediated immunity and increased il-4 expression ( p =0.032). the results revealed that the simultaneous use of multiple antigens and heterologous prime/boost strategy can enhance both humoral and cellular immune systems. moreover, subcutaneous injection of rgm-csf increases il-4 production and shifts the immune pattern to th2 . these strategies can potentially be used to develop an efficient hiv-1 vaccine.